Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials

[1]  R. Hotchkiss,et al.  Host-directed therapies for bacterial and viral infections , 2017, Nature Reviews Drug Discovery.

[2]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[3]  J. Ahn,et al.  Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with FGFR1 amplification: A single‐arm, phase 2 study , 2016, Cancer.

[4]  M. Kudo,et al.  Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma , 2016, Hepatology.

[5]  黄亚明,et al.  European Society of Clinical Microbiology and Infectious Diseases , 2016 .

[6]  M. Minden,et al.  A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia , 2016, Investigational New Drugs.

[7]  L. Seymour,et al.  A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191 , 2016, Leukemia & lymphoma.

[8]  R. Fimmers,et al.  Phase I trial of dovitinib (TKI258) in recurrent glioblastoma , 2016, Journal of Cancer Research and Clinical Oncology.

[9]  L. Amaral,et al.  Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis , 2016, PloS one.

[10]  A. Gaumann,et al.  Receptor tyrosine kinase inhibitors: Are they real tumor killers? , 2016, International journal of cancer.

[11]  Reto Guler,et al.  Host-directed drug therapy for tuberculosis. , 2015, Nature chemical biology.

[12]  R. Raqib,et al.  Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial , 2015, PloS one.

[13]  R. Wilkinson,et al.  Phenylbutyrate Is Bacteriostatic against Mycobacterium tuberculosis and Regulates the Macrophage Response to Infection, Synergistically with 25-Hydroxy-Vitamin D₃ , 2015, PLoS pathogens.

[14]  D. Kalman,et al.  New tricks for old dogs: countering antibiotic resistance in tuberculosis with host‐directed therapeutics , 2015, Immunological reviews.

[15]  Md Abdul Alim Al-Bari,et al.  Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases , 2015, The Journal of antimicrobial chemotherapy.

[16]  R. Jain,et al.  Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery , 2015, Proceedings of the National Academy of Sciences.

[17]  R. Kay,et al.  Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion , 2014, EMBO molecular medicine.

[18]  G. Kaplan,et al.  Metformin as adjunct antituberculosis therapy , 2014, Science Translational Medicine.

[19]  S. Halford,et al.  A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study , 2014, Clinical Cancer Research.

[20]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[21]  R. W. Beerman,et al.  Interception of host angiogenic signalling limits mycobacterial growth , 2014, Nature.

[22]  M. Gennaro,et al.  Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. , 2014, The Journal of antimicrobial chemotherapy.

[23]  N. Sinha,et al.  Pathogenicity of Mycobacterium tuberculosis Is Expressed by Regulating Metabolic Thresholds of the Host Macrophage , 2014, PLoS pathogens.

[24]  A. Sher,et al.  Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk , 2014, Nature.

[25]  Anne E Carpenter,et al.  Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth , 2014, PLoS pathogens.

[26]  E. R. van den Heuvel,et al.  Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis , 2013, Journal of clinical psychopharmacology.

[27]  P. Cardona,et al.  Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. , 2013, The Journal of infectious diseases.

[28]  A. Newton,et al.  Protein kinase C pharmacology: refining the toolbox. , 2013, The Biochemical journal.

[29]  Y. Kalaidzidis,et al.  Integration of chemical and RNAi multiparametric profiles identifies triggers of intracellular mycobacterial killing. , 2013, Cell host & microbe.

[30]  L. Manni,et al.  Nerve growth factor: from the early discoveries to the potential clinical use , 2012, Journal of Translational Medicine.

[31]  T. Ottenhoff.  The knowns and unknowns of the immunopathogenesis of tuberculosis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[32]  T. Ottenhoff.  New pathways of protective and pathological host defense to mycobacteria. , 2012, Trends in microbiology.

[33]  D. Kalman,et al.  Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. , 2011, Cell host & microbe.

[34]  G. Kaplan,et al.  Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid – Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs , 2011, PLoS pathogens.

[35]  G. Kaplan,et al.  Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. , 2011, The American journal of pathology.

[36]  S. Feller,et al.  Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers , 2011, Cell Communication and Signaling.

[37]  G. Kaplan,et al.  Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in the Lungs of Infected Mice , 2011, PloS one.

[38]  J. Flynn,et al.  HIV-1/Mycobacterium tuberculosis Coinfection Immunology: How Does HIV-1 Exacerbate Tuberculosis? , 2011, Infection and Immunity.

[39]  J. Blanchard,et al.  The chemical biology of new drugs in the development for tuberculosis. , 2010, Current opinion in chemical biology.

[40]  W. Bishai,et al.  Epidemiology and challenges to the elimination of global tuberculosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  S. Eckhardt,et al.  Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models , 2010, Clinical Cancer Research.

[42]  Dhiraj Kumar,et al.  Identification of Host-Dependent Survival Factors for Intracellular Mycobacterium tuberculosis through an siRNA Screen , 2010, PLoS pathogens.

[43]  Sarman Singh,et al.  Genome-wide Analysis of the Host Intracellular Network that Regulates Survival of Mycobacterium tuberculosis , 2010, Cell.

[44]  Tangui Maurice,et al.  The pharmacology of sigma-1 receptors. , 2009, Pharmacology & therapeutics.

[45]  Stewart T. Cole,et al.  High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors , 2009, PLoS pathogens.

[46]  S. Bonner-Weir,et al.  Mutations at the BLK locus linked to maturity onset diabetes of the young and β-cell dysfunction , 2009, Proceedings of the National Academy of Sciences.

[47]  Tom H M Ottenhoff,et al.  Overcoming the global crisis: “Yes, we can”, but also for TB … ? , 2009, European journal of immunology.

[48]  Stewart T. Cole,et al.  Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.

[49]  Amit Singhal,et al.  Synthetic EthR inhibitors boost antituberculous activity of ethionamide , 2009, Nature Medicine.

[50]  Mladen Vinković,et al.  Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. , 2009, Journal of medicinal chemistry.

[51]  S. Skaper.  The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. , 2008, CNS & neurological disorders drug targets.

[52]  Jacques Neefjes,et al.  Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1 , 2007, Nature.

[53]  J. Pieters,et al.  Survival of Mycobacteria in Macrophages Is Mediated by Coronin 1-Dependent Activation of Calcineurin , 2007, Cell.

[54]  M. Mann,et al.  Robust Salmonella metabolism limits possibilities for new antimicrobials , 2006, Nature.

[55]  T. Ottenhoff,et al.  Phenotypic and functional profiling of human proinflammatory type‐1 and anti‐inflammatory type‐2 macrophages in response to microbial antigens and IFN‐γ‐ and CD40L‐mediated costimulation , 2006, Journal of leukocyte biology.

[56]  Roger Finch,et al.  Lack of development of new antimicrobial drugs: a potential serious threat to public health. , 2005, The Lancet. Infectious diseases.

[57]  Hong Chang,et al.  CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. , 2004, Blood.

[58]  S. Gauld,et al.  Src-family kinases in B-cell development and signaling , 2004, Oncogene.

[59]  Vojo Deretic,et al.  Cell biology of mycobacterium tuberculosis phagosome. , 2004, Annual review of cell and developmental biology.

[60]  Matthijs Kramer,et al.  Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[61]  S. Grinstein,et al.  Salmonella redirects phagosomal maturation. , 2004, Current opinion in microbiology.

[62]  M. Sugiyama,et al.  Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation. , 2002, European journal of pharmacology.

[63]  R. L. Santos,et al.  Animal models of Salmonella infections: enteritis versus typhoid fever. , 2001, Microbes and infection.

[64]  S. Kaufmann,et al.  How can immunology contribute to the control of tuberculosis? , 2001, Nature Reviews Immunology.

[65]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[66]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[67]  Jacques Neefjes,et al.  Modulation of the Major Histocompatibility Complex Class II–Associated Peptide Repertoire by Human Histocompatibility Leukocyte Antigen (Hla)-Do , 2000, The Journal of experimental medicine.

[68]  M. Blaustein,et al.  Sodium/calcium exchange: its physiological implications. , 1999, Physiological reviews.

[69]  C. Heckman,et al.  The sevenfold way of PKC regulation. , 1998, Cellular signalling.

[70]  J. Trowsdale,et al.  HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading , 1997, Current Biology.

[71]  M. Gilmore,et al.  Simplified agar plate method for quantifying viable bacteria. , 1997, BioTechniques.

[72]  T. Ottenhoff,et al.  A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. , 1993, Journal of immunology.

[73]  A. Stalder,et al.  Expression of functional trk protooncogene in human monocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[74]  W. Westerhof,et al.  Phagocytosis by normal human melanocytes in vitro. , 1993, Experimental cell research.

[75]  W. Osterrieder,et al.  In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action. , 1989, Journal of Cardiovascular Pharmacology.

[76]  M. Goppelt‐Struebe,et al.  Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner. , 2014, The international journal of biochemistry & cell biology.

[77]  S. Keyse,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Human & experimental toxicology.

[78]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .